- For the first time ever, a demonstration version of one of
Recursion's Compound Intelligence tools to explore maps of biology
and chemistry is open for anyone to use
- RxRx3, the underlying dataset released alongside MolRec™, spans
almost the entire human genome and is 76 times larger than all
previous datasets released by Recursion combined, yet it represents
less than 1% of Recursion's total data universe
SALT
LAKE CITY, Jan. 26, 2023 /PRNewswire/ -- Recursion
(NASDAQ: RXRX), the clinical-stage biotechnology company
industrializing drug discovery by decoding biology, announced the
public release of MolRec™ - one of its many interactive
internal tools to explore the company's proprietary maps of biology
and chemistry. Just as a regular map is a navigation tool in the
physical world, Recursion's maps are designed to help scientists
understand the topology and connectedness of human biology and
chemistry to navigate the path to new medicines more efficiently.
In addition, Recursion released RxRx3, its largest open-source
cellular imaging dataset to date, spanning approximately 2.2
million images across the human genome and 1,600 commercially
available compounds in a single cell type.
RxRx3 is 76 times larger than all previous
Recursion datasets combined, yet it's >1% of Recursion's total
data universe.
"With the release of MolRec™ and the RxRx3 dataset, anyone
in the world can now explore some of the same insights that our
scientists are using to generate novel therapeutic hypotheses and
advance new discovery programs," said Ben
Mabey, Chief Technology Officer at Recursion.
"MolRec™ represents a small portion of many applications built
upon our proprietary datasets that are helping us industrialize the
drug discovery process."
Recursion's maps are constructed using high-dimensional datasets
generated in-house in the company's highly automated and
industrialized laboratories. The foundational dataset uses a
technique known as phenomics, in which machine learning algorithms
extract structured data from billions of images of human cells that
have been manipulated by genome-wide CRISPR-Cas9 knockouts,
chemical compounds, or other reagents. Digital representations of
cells are compared and contrasted to predict trillions of
relationships across biology and chemistry — even without
physically testing all of the possible combinations. To date,
Recursion has generated more than 3 trillion searchable gene and
compound relationships across all of its maps that are used to
identify novel insights and advance new therapeutic programs,
unconstrained by human bias or existing scientific literature.
The RxRx3 dataset and the part of MolRec™ available to the
public are built using a small subset of Recursion's experimental
inputs: Approximately 1,600 commercially-available compounds at
eight doses each and 17,000 gene knockouts. The majority of genes
are anonymized in the dataset, enabling people to explore and learn
from this massive dataset while protecting Recursion's business
interests. The application can be used to uncover known and novel
compound-compound as well as compound-gene relationships.
Importantly, MolRec™ provides information on a compound's
potency and insight into its potential mechanism of action. Many of
the insights found within MolRec™ have not been documented in
scientific literature.
"Instead of looking narrowly at a handful of diseases with
existing therapeutic hypotheses, our maps allow us to direct our
focus toward unknown or unexplored relationships across biology and
chemistry to pursue areas of high unmet need for patients," said
Chris Gibson, Ph.D., Co-Founder and
Chief Executive Officer at Recursion. "In essence, it's turning
drug discovery from a bespoke and artisanal process into a search
problem. This app and dataset release give people a peek under the
hood of what we are building here at Recursion and will whet the
appetite of many interested in this field."
The MolRec™️ app and the corresponding dataset, RxRx3, were
released during Recursion's Download Day, the company's first
R&D Day. Sell-side equity research analysts, institutional
investors, and investment bankers joined members of Recursion's
executive team and board of directors for an engaging, in-person
event at the company's headquarters in Salt Lake City, Utah. The day consisted of
presentations on Recursion's technology, science, pipeline and
partnerships, as well as demonstrations of Recursion's mapping and
navigating technology and tours of the company's highly automated
laboratories. A recording of the presentations is available on the
investor relations section of the company's website at
ir.recursion.com.
To begin exploring Recursion's MolRec™ app, or to download
the RxRx3 dataset, visit: rxrx.ai.
For those who are interested in connecting with Recursion to
learn more about its mapping & navigating technology, contact:
partner@recursionpharma.com.
About Recursion
Recursion is the clinical-stage
biotechnology company industrializing drug discovery by decoding
biology. Enabling its mission is the Recursion OS, a platform built
across diverse technologies that continuously expands one of the
world's largest proprietary biological and chemical datasets.
Recursion leverages sophisticated machine-learning algorithms to
distill from its dataset a collection of trillions of searchable
relationships across biology and chemistry unconstrained by human
bias. By commanding massive experimental scale — up to millions of
wet lab experiments weekly — and massive computational scale —
owning and operating one of the most powerful supercomputers in the
world, Recursion is uniting technology, biology and chemistry to
advance the future of medicine.
Recursion is headquartered in Salt
Lake City, where it is a founding member of BioHive, the
Utah life sciences industry
collective. Recursion also has offices in Toronto, Montreal and the San
Francisco Bay Area. Learn more at www.Recursion.com, or
connect on Twitter and LinkedIn.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Forward-Looking Statements
This press release contains
information that includes or is based upon "forward-looking
statements" within the meaning of the Securities Litigation Reform
Act of 1995, including, without limitation, those regarding the
closing of the private placement, registration of the shares of
Class A common stock being issued and sold in the private
placement, Recursion's use of the proceeds from the private
placement, Recursion's preclinical and clinical programs, and all
other statements that are not statements of historical facts.
Forward-looking statements may or may not include identifying words
such as "intend," "may," "expect," "plan," and similar terms. These
statements are subject to known or unknown risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied in such statements, including but not limited
to: challenges inherent in pharmaceutical research and development,
including the timing and results of preclinical and clinical
programs, where the risk of failure is high and failure can occur
at any stage prior to or after regulatory approval due to lack of
sufficient efficacy, safety considerations, or other factors; our
ability to leverage and enhance our drug discovery platform; our
ability to obtain financing for development activities and other
corporate purposes; the success of our collaboration activities;
our ability to obtain regulatory approval of, and ultimately
commercialize, drug candidates; and other risks and uncertainties
such as those described under the heading "Risk Factors" in our
filings with the SEC, including our most recent Quarterly Report on
Form 10-Q and our Annual Report on Form 10-K. All forward-looking
statements are based on management's current estimates,
projections, and assumptions, and Recursion undertakes no
obligation to correct or update any such statements, whether as a
result of new information, future developments, or otherwise,
except to the extent required by applicable law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/recursion-releases-molrec-a-compound-intelligence-tool-for-drug-discovery-alongside-the-largest-of-its-kind-open-source-dataset-during-first-rd-day-301731500.html
SOURCE Recursion